Creso making progress across its Lifestyle cannabis portfolio

|

Published 11-SEP-2018 11:04 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Creso Pharma Ltd (ASX:CPH) has advised the market that it is making good progress with its Lifestyle portfolio.

The company is achieving this goal while still strengthening its already solid global positions in neutraceuticals, animal health and therapeutic products.

Progress was made across a number of fronts in August and this was acknowledged by investors with the company’s share price increasing circa 25% after negotiating an agreement to commercialise cannaQIX® in Austria and targeted Eastern and Northern European countries

Creso’s broader portfolio is designed with unique products to appeal to a diversified global consumer base.

In keeping with all of its product categories, therapeutics, nutraceuticals, animal health and topicals, Creso’s strategy with Lifestyle products is to identify and secure agreements with reputable commercial partners.

These partners provide market knowledge and the ability to launch and distribute products within an established network, allowing Creso to expand quickly across global markets.

Of course, Creso remains a speculative stock so investors should seek professional financial advice if considering this stock for their portfolio.

Cannabis infused beers gaining popularity

Within Creso’s Lifestyle portfolio, partnerships are being discussed across many of the key markets to develop and launch products.

Creso has progressed its joint venture with LGC Capital (LG:TSX.V) and the Baltic Beer Company - CLV Frontier Brands Pty Ltd - to bring innovative and relevant products to market quickly.

As consumers become more comfortable with the idea of cannabis-infused drinks, and following legalisation across some US states and in Canada, several of the global leaders in alcoholic beverages, including Molson Coors Brewing Co and Constellation Brands Inc. are investing heavily in developing cannabis-infused beverages.

Creso also said that another beverage giant, Diageo, is rumoured to be entering the field.

CLV joint venture provides global reach

CLV Frontier Brands will have wide-spread commercialisation reach across numerous continents and intends to make full use of the networks of all three companies for marketing and distribution, strictly in compliance with all local and international laws.

CLV is currently in discussions with distributors in Canada, where there is a large consumer base with an appetite for cannabis derived products and the view is that there will be enhanced demand in relation to the legislation of recreational cannabis in October 2018.

Branding for the range of Old Boy Mary Jane (OBMJ) beers has been finished and samples have been sent to Europe, Israel and Australia.

The brand website, www.obmj.beer CLV Frontier Brands is available and will formally launch its premium beers in the United Kingdom on October 2, 2018 in conjunction with the London Boutique Bar Show (www.boutiquebarshow.com) which exclusively promotes new and high-quality drinks brands to the UK industry.

CLV Frontier Brands beverages create a world of new products that deliver a uniquely enjoyable drinking experience.

Initiatives such as social media campaigns are being run to ensure organic growth and awareness for the Old Boy Mary Jane brand.

CLV Frontier Brands will partner with Flagship Brands in the UK who understand the UK market and are well respected having worked with various alcoholic drinks brands over the years.

CLV will also launch OBMJ at the key beer show Bar Convent Berlin (www.barconvent.com/de) between October 8 and October 10, providing extensive exposure to the European bar scene.

Launch of cannabis infused foods

In tandem with its strong progress on the beverages front, Creso has been laying the foundations for a December quarter launch of cannabis infused food products.

The high-growth functional foods space provides lucrative opportunities for more cannabis-infused products.

In partnership with Felchlin Switzerland, Creso’s terpene-enriched functional MÒÁ line of chocolate brands is now in the hands of numerous businesses globally with the aim of bringing products to market by the December quarter of 2018.

Felchlin is a high end genuine Swiss chocolate producer and operates in line with Creso’s quality standards.

Discussing Creso’s achievements in terms of developing diversified products that can be distributed in multiple global markets, chief executive and founder, Dr. Miri Halperin Wernli said, “Creso has seen the potential for cannabis-enriched food and beverages.

“We are in the process of discussing agreements with partners to enter this market in countries across the world.

“Big beverage companies have seen the opportunity as consumer appetites grow for products infused with cannabis and enhanced with terpenes.

“Creso, with its established presence in the US and Canada, where the biggest potential currently lies, is perfectly positioned for its products to become a leader in this new and emerging field.”

Creso continues to identify and secure agreements with experienced commercial partners across Europe, Israel, Australia and the Americas, further expanding the global reach of its Lifestyle products to increase the overall success and reach of all Creso owned brands.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X